Literature DB >> 21498081

Radiosynthesis of a new PSMA targeting ligand ([18F]FPy-DUPA-Pep).

Noeen Malik1, Hans-Jürgen Machulla, Christoph Solbach, Gordon Winter, Sven N Reske, Boris Zlatopolskiy.   

Abstract

Due to the specificity of expression of PSMA (prostate specific membrane antigen) particularly in prostate cancer cells (e.g. LNCaP), numerous PSMA ligands have been synthesized until now. In the current study, we synthesized DUPA-Pep having 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid (DUPA) linked via 8-aminooctanoic acid to two phenylalanine residues and chose 6-[(18)F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester [(18)F]FPy-TFP as a prosthetic group for coupling. [(18)F]FPy-DUPA-Pep was obtained in a radiochemical yield of 48±0.9% (decay uncorrected) within 50 min with a chemical purity of >98%.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21498081     DOI： 10.1016/j.apradiso.2011.03.041

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN： 0969-8043            Impact factor:   1.513


  13 in total

1.  2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Authors:  Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

Review 2.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 3.  Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation.

Authors:  S Lütje; M Rijpkema; W Helfrich; W J G Oyen; O C Boerman
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

4.  Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro.

Authors:  Noeen Malik; Benjamin Baur; Gordon Winter; Sven N Reske; Ambros J Beer; Christoph Solbach
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

Review 5.  Prostate-specific membrane antigen as a target for cancer imaging and therapy.

Authors:  A P Kiess; S R Banerjee; R C Mease; S P Rowe; A Rao; C A Foss; Y Chen; X Yang; S Y Cho; S Nimmagadda; M G Pomper
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-07-24       Impact factor: 2.346

6.  Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities.

Authors:  Zora Novakova; Jiri Cerny; Cindy J Choy; Jessie R Nedrow; Joeseph K Choi; Jacek Lubkowski; Clifford E Berkman; Cyril Barinka
Journal:  FEBS J       Date:  2015-11-05       Impact factor: 5.542

7.  Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep.

Authors:  Benjamin Baur; Christoph Solbach; Elena Andreolli; Gordon Winter; Hans-Jürgen Machulla; Sven N Reske
Journal:  Pharmaceuticals (Basel)       Date:  2014-04-29

8.  Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007.

Authors:  Stephanie Robu; Alexander Schmidt; Matthias Eiber; Margret Schottelius; Thomas Günther; Behrooz Hooshyar Yousefi; Markus Schwaiger; Hans-Jürgen Wester
Journal:  EJNMMI Res       Date:  2018-04-12       Impact factor: 3.138

9.  Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models.

Authors:  Vincent Bouvet; Melinda Wuest; Hans-Soenke Jans; Nancy Janzen; Afaf R Genady; John F Valliant; Francois Benard; Frank Wuest
Journal:  EJNMMI Res       Date:  2016-05-04       Impact factor: 3.138

10.  In vivo Molecular Imaging of Glutamate Carboxypeptidase II Expression in Re-endothelialisation after Percutaneous Balloon Denudation in a Rat Model.

Authors:  Heike Endepols; Felix M Mottaghy; Sakine Simsekyilmaz; Jan Bucerius; Felix Vogt; Oliver Winz; Raphael Richarz; Philipp Krapf; Bernd Neumaier; Boris D Zlatopolskiy; Agnieszka Morgenroth
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.